Objective: Transvaginal mesh surgery for pelvic organ prolapse has been widely performed in Japan, but polypropylene mesh has not been used in Japan since the ban on TVM using polypropylene mesh in the United States. Currently, polytetrafluoroethylene mesh ORIHIME® is the only mesh available for TVM in Japan. Although polytetrafluoroethylene is a safe material, its low coefficient of friction and insufficient adhesion to the surrounding tissue make it difficult to maintain the mesh position when it is used in the transvaginal mesh surgery. The aim of this study was to evaluate the feasibility of TVM-A2 using ORIHIME®.
Methods: One hundred cases of TVM-A2 were included in the study. The patients were randomly assigned to two groups: the ORIHIME® group (Group O) and the Polyform group (Group P). With 50 patients in each group, the complications and recurrences up to the fourth year were compared. Surgeries were performed using the TVM-A2 method. Statistical analysis was performed using EZR.
Results: There were no significant differences in baseline parameters between the two groups. We observed no perioperative complications, and saw one case of postoperative abscess formation in Group O, which resolved successfully after incision and drainage. The 4-year recurrence rate was significantly higher in Group O.
Conclusion: As the recurrence rate was significantly higher in Group O, we conclude that TVM-A2 using ORIHIME® which is the same procedure as TVM-A2 using polypropylene mesh is not feasible in repairing the pelvic organ prolapse.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/iju.15506 | DOI Listing |
Biomed Mater
December 2024
Department of Chemical Engineering, Indian Institute of Technology - Bombay, Powai, Mumbai 400 076, Mumbai, Maharastra, 400076, INDIA.
Mechanical non-conformance of conventionally used transvaginal non-degradable meshes has led to complications like organ perforation, dyspareunia caused by mesh stiffness, and stress shielding. In this study, we have solved the dire need of mimicking the mechanical properties of vaginal wall by designing and developing a soft and elastic mesh made of polycaprolactone (PCL), citric acid modified polyethylene glycol (PEGC) and zinc oxide (ZnO) prepared through electrospinning and is tested in-vitro and in-vivo. Mesh containing 90:10:0.
View Article and Find Full Text PDFInt J Womens Health
December 2024
Department of Urology, Università "la Sapienza", ICOT, Latina, Italy.
Purpose: Surgical repair is considered the mainstay of genital prolapse management. Several procedures are available both by vaginal and abdominal route, with and without mesh augmentation. The Italian UroGynecology Association (AIUG) promoted this survey with the aim of evaluating current variations in the surgical management of various types of prolapse in different clinical settings and to compare practice amongst practitioners working in high- and medium/low-volume centers.
View Article and Find Full Text PDFJ Clin Med
December 2024
Tricomed S.A., Świętojańska 5/9, 93-493 Lodz, Poland.
The prevalence of POP in women ranges from 30-40%, with 10-20% requiring surgical intervention. Annually, over 225,000 surgical procedures for POP are performed in the United States. The severity of prolapse is assessed using the four-stage POP-Q system, which facilitates clinical research by providing a standardized measure of defect severity.
View Article and Find Full Text PDFNeurourol Urodyn
November 2024
Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Eur J Obstet Gynecol Reprod Biol
January 2025
Women Health Center, International Medical Center (IMC) Hospital, Jeddah, Saudi Arabia.
Objective: This study evaluates the outcomes of modified transvaginal mesh (TVM) Surelift in managing advanced pelvic organ prolapse (POP) over a 3-year follow-up period, focusing on surgical success, functional improvement, and sonographic findings.
Methods: A retrospective review was conducted on 99 women who underwent Surelift System surgery for advanced POP Stage III and IV between July 2018 to January 2020. Objective evaluation included Pelvic Organ Prolapse Quantification (POP-Q), multichannel urodynamic (UDS), and introital 2D ultrasonographic measurement.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!